Study of BMS-986453 for Relapsed or Refractory Multiple Myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new drug, BMS-986453, for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to see if it is safe and works against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has come back or is not responding to treatment.
- You have already tried at least two types of treatments, including a proteasome inhibitor (like bortezomib) and an immunomodulatory drug (like lenalidomide).
- Your disease got worse during or within 12 months of your last treatment.
- You are generally able to care for yourself (ECOG performance status 0 or 1).
- Your organs (like kidneys, liver, and heart) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called BMS-986393 (a type of CAR T-cell therapy) compared to standard treatments for adults with multiple myeloma that has come back or is not responding to therapy, and who have already been treated with lenalidomide (Revlimid). The goal is to see if the new treatment works better.
This early-phase study tests how safe a new drug (CC-92480) is and how much it stays in the body, when given with other standard or study treatments. It’s for people whose multiple myeloma has come back or did not respond after prior therapy, with the goal of improving disease control.
This trial tests if a new medicine called linvoseltamab, alone or combined with carfilzomib, works better than the usual treatments for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior therapies.
This trial tests a new drug called MBS314 for people whose multiple myeloma has returned or stopped responding to other treatments. The goal is to see if MBS314 can help shrink or control the myeloma.
This trial tests a new treatment called BCD-248 for people whose multiple myeloma has come back or stopped responding to at least two prior treatments. It aims to see if it is safe and effective.
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
Hear when a new Relapsed and/or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.